ISIS PHARMACEUTICAL (ISI BE) stock market data APIs
€62.0958
0.64(1%)
as of March 18, 2026
Try our APIs with
free plan!
ISIS PHARMACEUTICAL Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for ISI.BE.
Prev. Close
62.0958
Open
62.7385
High
63.4161
Low
61.7578
52 wk Range
22.5-70.66
Market Cap
3 685 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ISIS PHARMACEUTICAL data using free add-ons & libraries
Get ISIS PHARMACEUTICAL Fundamental Data
ISIS PHARMACEUTICAL Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-25
- EPS/Forecast: -1.22
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ISIS PHARMACEUTICAL News
New
Ionis Priority Review And DAWNZERA Data Reframe Rare Disease Growth Story
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Ionis Pharmaceuticals received FDA Priority Review for its supplemental New Drug Applicatio...
Olezarsen Priority Review and Expanding Rare Disease Franchise Could Be A Game Changer For Ionis (IONS)
In recent weeks, Ionis Pharmaceuticals announced that the FDA accepted a Priority Review for olezarsen in severe hypertriglyceridemia, released 2026 revenue guidance of US$800 million to US$825 millio...
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
CARLSBAD, Calif., February 27, 2026--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targete...
Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best strong buy healthcare stocks to invest in. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its fiscal Q4 and full-year 2025 earnings on ...
Get ISIS PHARMACEUTICAL fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
